ProCE Banner Activity

Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML

Slideset Download
Conference Coverage
In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger.

Released: December 08, 2016

Expiration: December 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen